We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Sinclair Pha | LSE:SPH | London | Ordinary Share | GB0033856740 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 31.80 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMSPH
RNS Number : 7220H
Sinclair Pharma PLC
22 August 2016
Sinclair Pharma plc
Notice of Results
London, 22 August 2016 - Sinclair Pharma plc (AIM: SPH.L) ("Sinclair" or "the Group"), the international company operating in the fast growing global aesthetics market, will announce its results for the six month period covering 1 January 2016 to 30 June 2016 on Wednesday 21 September 2016.
As previously announced, fully audited 18 month final results for the period 1 July 2015 to 31 December 2016 will be published in March 2017.
A briefing for analysts will be held at 09.30 BST at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD. A live audio webcast and slide presentation will also be available after the event at www.sinclairpharma.com.
-Ends-
For further information, please contact:
Sinclair Pharma plc Tel: +44 (0) 20 7467 6920 Chris Spooner/Alan Olby Peel Hunt LLP Tel: +44 (0) 20 7418 8900 James Steel/Oliver Jackson FTI Consulting Tel: +44 (0) 20 3727 1000 Ben Atwell/Brett Pollard
About Sinclair Pharma plc
Sinclair Pharma plc is an international company that operates in the fast growth, high gross margin, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments.
The Company is planning entry to multiple new geographic markets and line extension launches over the next few years. The group has an established sales and marketing presence in the leading EU markets' and a rapidly growing International division concentrated on the Emerging Markets through long term multi-product, multi-country, sales, marketing and distribution deals with key strategic partners.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORBLGDILGBBGLC
(END) Dow Jones Newswires
August 22, 2016 02:00 ET (06:00 GMT)
1 Year Sinclair Pharma Chart |
1 Month Sinclair Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
